Global clinical response in Cushing’s syndrome patients treated with mifepristone

OBJECTIVE: Mifepristone, a glucocorticoid receptor antagonist, improves clinical status in patients with Cushing’s syndrome (CS). We examined the pattern, reliability and correlates of global clinical response (GCR) assessments during a 6-month clinical trial of mifepristone in CS. DESIGN: Post hoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Katznelson, Laurence, Loriaux, D Lynn, Feldman, David, Braunstein, Glenn D, Schteingart, David E, Gross, Coleman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255292/
https://www.ncbi.nlm.nih.gov/pubmed/24102404
http://dx.doi.org/10.1111/cen.12332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255292/
https://www.ncbi.nlm.nih.gov/pubmed/24102404
http://dx.doi.org/10.1111/cen.12332

Ejemplares similares